arrow
A

Alexa B. Kimball

Beth Israel Deaconess Medical Center
H指数:82
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Bimekizumab在治疗中度至重度化脓性汗腺炎的患者中,显示出良好的安全性和高水平的疗效,治疗时间长达2年:来自两项III期随机对照试验及其开放标签扩展研究的合并结果

2025-11-150
PRE
A randomized, double-blind, placebo-controlled phase 2 study of eltrekibart, a novel septa-specific monoclonal antibody to CXCR1/2 ligands, in adults with hidradenitis suppurativa

一项关于eltrekibart(一种新型靶向CXCR1/2配体的 septa-specific 单克隆抗体)的随机、双盲、安慰剂对照的2期研究,用于治疗成人化脓性汗腺炎。

2025-10-060
PRE
The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa

hidradenitis suppurativa症状与影响日记:hidradenitis suppurativa新型患者报告结局的研制与心理测量学评价

2025-10-010
OAAI
The P2X7-NLRP3 inflammasome inhibitor AZD9056 has no significant effect on hidradenitis suppurativa clinical disease activity but restores cytokine production in peripheral blood mononuclear cells: Results of a phase 2 trial

P2X7-NLRP3炎症小体抑制剂AZD9056对痤疮 inversa 临床疾病活动性无显著影响,但可恢复外周血单核细胞的细胞因子产生:一项2期试验的结果

2025-09-270
PRE
Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies

Secukinumab在治疗中重度化脓性汗腺炎中的应用:SUNSHINE和SUNRISE三期研究的合并药代动力学与安全性结果

2025-08-210
OAAI
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
2024-12-011
PRE
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial

中重度 Hidradenitis suppurativa 患者中 Secukinumab 的长期有效性与安全性:SUNSHINE 和 SUNRISE 扩展试验第104周结果

2024-11-290
OA